The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,453 followers.

RT @Dr_Ivanoncologo: Interesting study where it is suggested that #Apatinib with a lower dose (=500 mg/d) has good efficacy and safety in t…

RT @Dr_Ivanoncologo: Interesting study where it is suggested that #Apatinib with a lower dose (=500 mg/d) has good efficacy and safety in t…

Interesting study where it is suggested that #Apatinib with a lower dose (=500 mg/d) has good efficacy and safety in the treatment of advanced #NSCLC after first-line #chemotherapy. @LungCancerSux @LungCancerHalfL @Lungsolutions https://t.co/v9r7CH7djw ht

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.